drugset / Trial / NCT01340885
Cognitive Decline in Non-demented PD
Phase 4
Completed
9 enrolled
Oregon Health and Science University
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).
Timeline
- Start
- 2011-01
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atomoxetine | Other / unclassified | 10 mg | — |
| Comparator | Atomoxetine | Other / unclassified | 30 mg | — |
| Comparator | Rivastigmine | Small molecule | 1.5 mg | — |
| Comparator | Rivastigmine | Small molecule | 4.5 mg | — |